



Guidelines &
Measures
Annual
Report

2022

2022 Guidelines & Measures Annual Report

TABLE OF CONTENTS

Guidelines Overview

- Guideline Publications
- Growth of Guidelines Program
 - Number of Published Guidelines, PCOS, Endorsements, and Adaptations
 - Guidelines Published by Disease Site
 - Volunteer Engagement

Journals

- Guideline Publication Views
- Top 5 Most Viewed JCO Publications
- Top 5 Most Viewed JCO OP Publications
- Top 5 Most Viewed JGO Publications

Website Analytics

- Page Views, Visits and Unique Visitors
- Top 10 Pages Visits
- Cancer.Net Website Analytics
- Social Media Statistics
 - Facebook
 - Twitter

Guidelines Derivative Products

- Guidelines Clinical Tools and Resources
- ASCO Guidelines Podcast Series
- Guidelines Pocketcards

Licensing

- Wolters Kluwer Top Reprints 2022

Current ASCO Guidelines Landscape

- All Published and In Progress Guidelines
- Guideline Priorities 2022-2023
- Cancer Journey Table

Collaborating Organizations

Measures Overview

- Measures by Disease Site
- Grants and Contracts
- TEP Activities

Stewarded Measures

- Federal Programs

- QPP MIPS
- MIPS Performance Year 2022 Historical Benchmark Results
- Core Quality Measures Collaborative
- ASCO Programs

[Volunteer Engagement](#)

[Collaborating Organizations](#)

2022 Guidelines Overview

Journal	Number of Publications
Journal of Clinical Oncology	26 guidelines (7 rapid updates), 1 editorial
Journal of Oncology Practice	8
Journal of Global Oncology	2
Total Publications:	37; 13 guidelines translated into Spanish

Guideline Publications by Disease Site

Breast

- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO)
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline and Rapid Update
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Rapid Update 1.0
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Rapid Update 2.0

Gastrointestinal

- Treatment of Metastatic Colon Cancer

Genitourinary

- Management of Metastatic Clear Cell Renal Cell Carcinoma
- Systemic Therapy Update on 177Lutetium-PSMA-617 For Metastatic Castration-Resistant Prostate Cancer Rapid Recommendation Update

Gynecologic

- Management and Care of Women with Invasive Cervical Cancer Resource-Stratified Guideline
- PARP Inhibitors in the Management of Ovarian Cancer Rapid Recommendation Update
- Secondary Prevention of Cervical Cancer Resource-Stratified Guideline

Head and Neck

- Immunotherapy and Biomarker Testing in Recurring and Metastatic Head and Neck Cancers

Molecular Testing/Biomarkers

- Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer

Melanoma

- Systemic Therapy for Melanoma Rapid Recommendation Update

Neurooncology

- Radiation Therapy for Brain Metastases Guideline Endorsement

Survivorship


- Integrative Medicine for Pain Management in Oncology


Supportive Care

- Exercise, Diet, and Weight Management During Cancer Treatment
- Use of Opioids for Adults with Pain from Cancer or Cancer Treatment

Thoracic

- Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIa Resectable Non-Small Cell Lung Cancer
- Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Living Guideline
- Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Living Guideline
- Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Living Guideline Update 2022.1
- Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Living Guideline Update 2022.1





- **6 2022 FASCO Awardees**
- **2 2022 Special Awardees**

Journals

Journal	Total 2022 Guideline publication views (including standards, endorsements, PCOs)
Journal of Clinical Oncology	1,444,545
Journal of Oncology Practice	102,391
Journal of Global Oncology	42,239

Top 5 Most Viewed JCO articles

- Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
- Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
- Antiemetics: ASCO Guideline Update

Top 5 Most Viewed JCO OP Articles

- Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy
- Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
- Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline Summary and Q&A
- Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

Top 5 Most Viewed JGO Articles

- Treatment of Patients with Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
- Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
- Management and Care of Patients with Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
- Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update
- Treatment of Patients with Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline


Journal	Most Read Articles
Journal of Clinical Oncology	21
Journal of Oncology Practice	6

Website Analytics

Page Views, Visits, and Unique Visitors by Month

	Page Views	Visits	Unique Visitors
January	51,401	13,709	11,190
February	50,482	13,935	11,264
March	53,256	15,197	12,606
April	43,846	12,754	10,645
May	51,019	15,658	12,939
June	60,185	17,615	14,472
July	55,983	15,723	12,754
August	54,455	15,548	12,626
September	56,109	16,184	13,278
October	55,683	16,744	13,778
November	44,545	13,737	11,406
December	33,877	10,632	9,031
Total	610,841	177,433	134,119

PAGE VIEWS BY COUNTRY (TOP 5)



Top 10 Pages Viewed in 2022

	Page Views	Visit	Unique Visitors
ASCO: Practice & Patients>Breast Cancer	95,284	50,101	37,446
ASCO: Practice & Patients>Guidelines, Tools, & Resources	78,864	54,191	42,143
ASCO: Practice & Patients>Supportive Care and Treatment-Related Issues	44,651	29,047	23,715
ASCO: Practice & Patients>Gastrointestinal Cancer	28,529	17,127	13,464
ASCO: Practice & Patients>Thoracic Cancer	26,423	15,009	10,835
ASCO: Practice & Patients>Genitourinary Cancer	20,572	13,002	10,159
ASCO: Practice & Patients>Patient and Survivor Care	15,538	10,983	8,813
ASCO: Practice & Patients>Gynecologic Cancer	14,163	8,494	6,336
ASCO: Practice & Patients>Head and Neck Cancer	13,151	8,263	6,379

Cancer.Net

ASCO Guidelines content is included on Cancer.Net as standalone articles or incorporated into Cancer.Net publications. In 2022, guidelines-related content received over **2.5 million page views**.

Top 10 Most Viewed Cancer.Net Content by Cancer Type

- Head and Neck Cancer - Diagnosis
- Cervical Cancer - Diagnosis
- Cervical Cancer - Follow-Up Care
- Head and Neck Cancer - Coping with Treatment
- Brain Tumor - Types of Treatment
- Breast Cancer - Diagnosis
- Breast Cancer - Types of Treatment
- Breast Cancer - Metastatic - Types of Treatment
- Colorectal Cancer - Types of Treatment
- Lung Cancer - Non-Small Cell - Types of Treatment

Social Media Statistics

Facebook

Shares	Likes	Link clicks	Impressions
295	885	1932	174,505

Twitter

Shares	Likes	Link Clicks	Impressions
597	339	810	233,829

Most Popular Tweets by Category

Content Summary	Likes	Shares	Link Clicks	Impressions
PARP Inhibitors rapid update	31	57	69	17,612
Somatic Genomic Testing PCO	13	26	31	17,084
Metastatic Renal Cell Clear Cell Carcinoma Guideline	18	47	62	15,723
Stage IV NSCLC Living Guideline open comment period	3	3	31	15,097
Integrative Medicine for Pain Management Guideline	31	40	39	14,555
Systemic Therapy for HER2+ Breast Cancer Guideline	18	34	57	11,743
Exercise, Diet, and Weight Management Guideline	29	51	61	10,368
Biomarkers for Systemic Therapy in Breast Cancer open comment period	4	10	26	10,008
Biomarkers for Adjuvant Endocrine Therapy Guideline	13	27	24	6,403

Guidelines Derivative Products

Clinical Tools & Resources

Total Tools: 98

Summary of Recommendations Tables: 26

- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-III A Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
- Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
- Management and Care of Patients with Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update

- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
- Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
- Therapy for Stage IV Non–Small-Cell Lung Cancer with Driver Alterations: ASCO Living Guideline
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
- Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
- Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update 1.0
- Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update
- Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- Systemic Therapy Update on ¹⁷⁷Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation
- Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2
- Therapy for Stage IV Non–Small-Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2022.2
- Use of Opioids for Adults with Pain From Cancer or Cancer Treatment: ASCO Guideline
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone-Receptor Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update 2.0

Slide Sets: 25

- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-III A Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
- Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
- Management and Care of Patients with Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
- Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
- Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
- Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update 1.0
- Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update
- Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- Systemic Therapy Update on ¹⁷⁷Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation
- Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Visual Abstracts/Graphics: 26

- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-III A Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
- Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
- Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update

- Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
- Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
- Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
- Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update 1.0
- Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update
- Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- Systemic Therapy Update on ¹⁷⁷Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation
- Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone-Receptor Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update 2.0

Algorithms & Flow Charts: 21

- Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update (1)
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline (4)
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update (1)
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update (1)
- Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update (4)
- Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline (1)
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline (1)
- Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update (1)
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline (2)

- Therapy for Stage IV Non–Small-Cell Lung Cancer: ASCO Living Guidelines (5)


ASCO Guidelines Podcast Series

Episodes Released in 2022: 25

Unique Downloads in 2022: 118,846


Total Unique Downloads All-Time: 294,128

2022 Monthly Downloads		
Month	# of Unique Downloads	# of Episodes Released
January	9,936	0
February	8,443	3
March	8,473	1
April	9,039	2
May	11,751	4
June	11,743	3
July	9,924	2
August	8,888	1
September	12,072	3
October	11,196	2
November	5,843	0
December	12,138	4



Top Downloaded Episodes in 2022:

1. Management of Stage III NSCLC Guideline: 3,788 downloads *released 12/22/21*
2. Management and Care of Patients with Invasive Cervical Cancer: Resource-Stratified Guideline Rapid Recommendation Update: 3,201 downloads *released 3/7/22*
3. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guideline Update: 3,134 downloads *released 4/19/22*
4. Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update: 3,109 downloads *released 8/4/22*
5. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer Provisional Clinical Opinion: 3,105 downloads *released 2/17/22*



Average # of Downloads of a New Episode in the First 30 Days

- 2018: 345
- 2019: 969.32
- 2020: 1050.76
- 2021: 1053.03
- **2022: 1442.64**

Guideline Pocketcards

*Information provided by Guideline Central

Number of New Titles Completed: 18 + 7 rapid updates

Number of Hard Copies Distributed: 10,045 (**up ~5,000 from 2021**)

Number of Online Purchases: 81

Members Who Have Claimed Free Access: Additional 110 claimed in 2022

2022 Pocketcard Titles

- Adjuvant Bisphosphonates and Other Bone-Modifying Agents
- Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer - Brain Metastases
- Biomarkers for Adjuvant Endocrine Therapy and Chemotherapy in Early Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Cervical Cancer Secondary Prevention update
- Clear Cell Renal Cell Carcinoma
- Exercise, Diet, and Weight Management During Cancer Treatment
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers
- Integrative Medicine for Pain Management in Oncology
- Invasive Cervical Cancer
- Metastatic Colorectal Cancer
- Metastatic HER2 Negative Breast Cancer Chemo and Targeted Therapy
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
- Opioids for Adults with Pain from Cancer or Cancer Treatment
- Secondary Prevention of Cervical Cancer
- Somatic Genomic Testing for Metastatic or Advanced Cancer
- Stage III Non-Small Cell Lung Cancer
- Therapies for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations
- Therapies for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations
- Non-Small Cell Lung Cancer - Adjuvant Therapy for Completely Resected Stages I-IIIa
- Systemic Therapy for Melanoma
- Chemotherapy HER2 Negative Metastatic Breast Cancer
- Invasive Cervical Cancer
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer

Licensing

*Information provided by Wolters Kluwer

Article title	Electronic qty	Print qty	Charge amount
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update		7500	\$63,855.00
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update		7500	\$53,295.00
Management of Immune-Related Adverse Events in Patients Treated with Immune		200	\$14,733.53

Checkpoint Inhibitor Therapy: ASCO Guideline Update			
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline	500		\$11,196.75
Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update		250	\$5,765.54

Current Guidelines Landscape

Published and In Progress Guidelines (as of 1/24/23)

Published Guidelines/Endorsements/Adaptations/Provisional Clinical Opinions (PCOs)

Breast Cancer

- Management of Hereditary Breast Cancer
- Management of Male Breast Cancer
- Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer
- Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
- Integrative Therapies During and After Breast Cancer Treatment
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- Estrogen and Progesterone Receptor Testing in Breast Cancer
- Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
- Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Endorsement
- Chemo- and Targeted Therapy for Women with HER2 Negative (or unknown), Advanced Breast Cancer
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women with Metastatic Breast Cancer
- Breast Cancer Survivorship
- The Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Endorsement
- Endocrine Therapy for Hormone-Receptor Positive Advanced Breast Cancer
- Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ Endorsement
- Postmastectomy Radiotherapy

- Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer
- Adjuvant Bisphosphonates and other Bone-Modifying Agents in Non-metastatic Breast Cancer
- Use Of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer
- The Role of Bone Modifying Agents in Metastatic Breast Cancer
- HER2 Testing in Breast Cancer
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
- Systemic Therapy for Patients with Advanced HER2-positive Breast Cancer
- Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases
- Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer Update
- Use of Endocrine Therapy for Breast Cancer Risk Reduction
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
- Management of the Axilla in Early-Stage Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
- Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: Rapid Recommendation Update 1
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Rapid Recommendation 2
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer Rapid Recommendation Update

Gastrointestinal Cancer

- Systemic Therapy for Advanced Hepatocellular Carcinoma
- Treatment of Locally Advanced Esophageal Carcinoma
- Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline
- Early Detection for Colorectal Cancer Resource-Stratified Guideline
- Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline
- Adjuvant Chemotherapy for Stage II Colon Cancer
- Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer Endorsement
- Hereditary Colorectal Cancer Syndromes Endorsement
- Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-EGFR Monoclonal Antibody Therapy
- Locally Advanced Pancreatic Cancer

- Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
- Metastatic Pancreatic Cancer Update
- Evaluating Susceptibility to Pancreatic Cancer
- Adjuvant Therapy for Resected Biliary Tract Cancer
- Duration of Oxaliplatin-containing Adjuvant Therapy for Stage III Colon Cancer
- Potentially Curable Pancreatic Adenocarcinoma
- Adjuvant Therapy for Stage II Colon Cancer
- Treatment of Metastatic Colorectal Cancer

Genitourinary Cancer

- Molecular Biomarkers in Localized Prostate Cancer
- Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer
- Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer
- Uses of Serum Tumor Markers in Adult Males with Germ Cell Tumors
- Non-hormonal Therapy for Men with Metastatic Hormone-refractory (Castration-resistant) Prostate Cancer Endorsement
- Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing
- Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer
- Adjuvant and Salvage Radiotherapy After Prostatectomy Endorsement
- Prostate Cancer Survivorship Care Guideline Endorsement
- Active Surveillance for the Management of Localized Prostate Cancer
- Muscle-invasive and metastatic bladder cancer Endorsement
- Management of Small Renal Masses
- Brachytherapy for Patients with Prostate Cancer
- Second—Line Hormonal Therapy for Castration-Resistant Prostate Cancer PCO
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
- Optimizing anti-cancer therapy in non-castrate metastatic prostate cancer
- Clinically Localized Prostate Cancer
- Hypofractionated Radiation Therapy for Localized Prostate Cancer
- Molecular and Cellular Diagnostics in Localized Prostate Cancer
- Optimum Imaging Strategies for Advanced Prostate Cancer
- Bone Health and Bone-targeted Therapies for Prostate Cancer
- Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer
- Systemic Therapy in Men with Castration-Resistant Prostate Cancer Rapid Recommendation Update

- Management of Metastatic Clear Cell Renal Cell Carcinoma

Gynecologic Cancer

- PARP Inhibitors in the Management of Ovarian Cancer
- Primary Prevention of Cervical Cancer Resource-Stratified Guideline
- Secondary Prevention of Cervical Cancer Resource-Stratified Guideline
- Neoadjuvant Chemotherapy for Ovarian Cancer
- Management and Care of Women with Invasive Cervical Cancer Resource-Stratified Guideline
- Postoperative Radiation Therapy for Endometrial Cancer Endorsement
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
- Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: Resource Stratified Guideline
- PARP Inhibitors in the Management of Ovarian Cancer: Rapid Recommendation Update

Head and Neck Cancer

- Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II to IVA Nasopharyngeal Carcinoma
- Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
- Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer
- Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
- Head and Neck Cancer Survivorship Care Endorsement
- Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma Endorsement
- Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
- Human Papillomavirus Testing in Head and Neck Carcinomas Endorsement
- Management of the neck in newly diagnosed squamous cell head and neck cancer
- De-escalation Protocols in the Management of p16+ Oropharyngeal Cancer
- Management of Salivary Gland Management
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers
- Hematologic Malignancies
- Role of Bone-Modifying Agents in Multiple Myeloma
- Initial Diagnostic Workup of Acute Leukemia Endorsement
- Treatment of Multiple Myeloma

Melanoma

- Systemic Therapy for Melanoma
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma
- Systemic Therapy for Melanoma: Rapid Recommendation Update

Molecular Testing and Biomarkers

- Estrogen and Progesterone Receptor Testing in Breast Cancer

- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- Circulating Tumor DNA Analysis in Patients with Cancer: An ASCO/CAP Joint Review
- Molecular Testing for the Selection of Patients with Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline Endorsement
- Somatic and Genomic Testing in Patients with Metastatic or Advanced Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer

Neuro-Oncology

- Recommendations on Disease Management for Patients with Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- Radiation Therapy for Glioblastoma Endorsement
- Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors
- Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults
- Treatment for Brain Metastases
- Radiation Therapy for Brain Metastases Endorsement

Patient and Survivor Care

- Palliative Care in the Global Setting Resource-Stratified Guideline
- Chronic Pain in Cancer Survivors
- Patient-Clinician Communication
- Interventions to Address Sexual Problems in People with Cancer Adaptation
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
- Fertility Preservation Patients with Cancer
- Screening, Assessment and Management of Fatigue in Adult Survivors of Cancer Adaptation
- Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults with Cancer Adaptation
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
- Management of Osteoporosis in Survivors of Adult Cancers with Non-Metastatic Disease
- Integrative Medicine for Pain Management in Oncology

Resource-Stratified

- Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline
- Early Detection for Colorectal Cancer Resource-Stratified Guideline
- Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline
- Management and Care of Women with Invasive Cervical Cancer
- Cervical Cancer Secondary Prevention/early disease
- Cervical Cancer Primary Prevention

- Palliative Care in the Global Setting
- Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: Resource-Stratified Guideline

Supportive Care and Treatment-Related Issues

- Metastatic Carcinoma and Myeloma of the Femur
- Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
- Management of Cancer Cachexia
- Use of Chemotherapy and Radiation Therapy Protectants
- Appropriate Chemotherapy Dosing for Obese Adult Patients with Cancer
- Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem Cell Transplantation Endorsement
- Central Venous Catheter Care for the Oncology Patient
- Hepatitis B Virus Screening for Patients with Cancer Prior to Therapy
- Use of White Blood Cell Growth Factors:
- Antiemetics
- The Integration of Palliative Care into Standard Oncology Care
- Platelet Transfusion for Patients with Cancer
- Patient-Clinician Communication
- Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy
- Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
- Use of Integrative Therapies During and After Breast Cancer Treatment Guideline Endorsement
- Antimicrobial Prophylaxis in Immunocompromised Patients
- Management of Cancer-associated Anemia with Erythropoiesis-Stimulating Agents (ASCO/ASH)
- Medication-Related Osteonecrosis of the Jaw
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
- Management of Dyspnea in Advanced Cancer
- Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
- Salivary Gland Hypofunction and/or Xerostomia Induced by Non-Surgical Cancer Therapies
- Management of Immune-Related Adverse Events in Patients Treatment with Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Exercise, Diet, and Weight Management During Cancer Treatment

Thoracic Cancer

- The role of CT screening for lung cancer in clinical practice
- Epidermal Growth Factor Receptor (EGFR) Mutation Testing for People with Advanced Non-Small Cell Lung Cancer Considering an EGFR Tyrosine-Kinase (TKI) Inhibitor
- Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Endorsement
- Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations
- Treatment of Small Cell Lung Cancer: Endorsement
- Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer Endorsement
- Treatment of Malignant Pleural Mesothelioma
- Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Endorsement
- Lung Cancer Surveillance After Definitive Curative-Intent Therapy
- Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A Resectable Non-Small Cell Lung Cancer
- Radiation Therapy for Small Cell Lung Cancer
- Management of Stage III NSCLC

Spanish Language Translations

- Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
- Management of Metastatic Clear Cell Renal Cell Carcinoma
- Management and Care of Women with Invasive Cervical Cancer Resource-Stratified Guideline
- Systemic Therapy for Melanoma
- Radiation Therapy for Brain Metastases Guideline Endorsement
- Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy
- Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Exercise, Diet, and Weight Management During Cancer Treatment
- Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A Resectable Non-Small Cell Lung Cancer

- Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations
- Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Standards

- Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology
- Safe Handling of Hazardous Drugs: ASCO Standards
- Patient-Centered Standards for Medically Integrated Dispensing
- Oncology Medical Home: ASCO and COA Standards
- Telehealth in Oncology: ASCO Standards and Practice Recommendations

De Novo Guidelines & Updates /PCOs/Endorsements in Development

Breast

- Adjuvant Endocrine Therapy for Breast Cancer Update
- Germline Mutation Testing in Breast Cancer
- HER2 Testing in Breast Cancer Update
- Metastatic Breast Cancer: Resource Stratified Guideline Adaptation
- Postmastectomy Radiotherapy Update

Gastrointestinal

- Neoadjuvant Therapy for Rectal Cancer
- Systemic Therapy for Neuroendocrine Tumors
- Targeted Therapy and Immunotherapy for Advanced Cholangiocarcinoma

Genitourinary

- Germline Mutation Testing in Prostate Cancer
- Metastatic Systemic Castration Resistant Prostate Cancer Update

Gynecologic

- NACT for Newly Diagnosed, Advanced Ovarian Cancer
- The Role of Postoperative Radiation Therapy for Endometrial Cancer (endorsement)
- Treatment of Endometrial Cancer

Head and Neck

- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers
- Consideration of Dental Care and Osteonecrosis in Patients Treated with Radiotherapy for Head and Neck Cancer –joint guideline with ISOO/MASCC
- Transoral Robotic Surgery for Oropharynx Cancer: Optimizing patient selection in HPV+ Oropharyngeal Cancer and Use of Adjuvant Therapy

Melanoma

- Systemic Therapy for Melanoma

Multi-Site

- Geriatric Assessment Update
- Germline Genetic Testing
- Use of cfDNA in Diagnosis and Monitoring in Solid Tumors and Lymphomas

Resource-Stratified

- Metastatic Breast Cancer RSG Adaptation
- Supportive Care
- Medical Cannabis in Adults with Cancer
- Opioid Conversion
- Vaccination of Adults with Cancer
- Venous Thromboembolism Update
- Patient-Clinical Communication Update
- Integration of Palliative Care into Standard Oncology Care Update

Survivorship

- Adolescent and Young Adult Survivorship
- Management of Cancer During Pregnancy
- Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults with Cancer

Standards

- Chemotherapy Safety Standards
- Integration of Palliative Care into Standard Oncology Care Update

Thoracic

- Systemic Therapy for Small Cell Lung Cancer
- Treatment of Malignant Pleural Mesothelioma Update

Guideline Priorities 2022-2023

Breast Cancer

- Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (Update)
- Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer (Update)
- Use of Endocrine Therapy for Breast Cancer Risk Reduction (Update)
- Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer (Update)
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer (Update)

Gastrointestinal Cancer

- Systemic Therapy (including Targeted Therapy) for Biliary Tract Cancer (New)
- Systemic Therapy for Advanced Hepatocellular Carcinoma (Update)
- Perioperative Management of Gastric Cancer with Diagnostic Laparoscopy and Nodal Dissection and Pathology (New)
- Treatment Options for Locoregional and Metastatic Small Bowel/Ampullary Cancer (New)
- Treatment Options for Anal Cancer (New)

Genitourinary Cancer

- Post-Operative Radiotherapy After Prostatectomy (Update of an Endorsement)
- Primary Tumor-Directed and Metastasis-Directed Local Therapy in Metastatic Prostate Cancer (New)
- Genitourinary Cancers Survivorship (New)
- Special Considerations for Elderly Patients with Genitourinary Cancers (New)
- Adjuvant Treatment of Localized and Oligometastatic Renal Clear Cell Cancer After Definitive Therapy (New)

Gynecologic Cancer

- First Platinum-Sensitive Ovarian Cancer Recurrence (New)
- Gynecologic Cancers Survivorship (New)
- Treatment of Invasive Cervical Cancer (New)
- Recurrent Endometrial Cancer (New)

Head and Neck Cancer

- Use of Systemic Treatment in the Management of Advanced Thyroid Cancer (New)
- Management of Advanced Cutaneous Squamous Cell of the Head and Neck (New)
- Management of Locoregionally Recurrent Head and Neck Cancer (New)
- Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer (Update)
- Management of Head and Neck Cancers in the Very Elderly (80+) and/or Frail Patient Population (New)

Hematological Malignancies

- Treatment of Multiple Myeloma (Update)
- New Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (New)
- New Treatment of Aggressive Lymphomas with a Focus on B Cell Lymphoma (New)
- New Risk-Based Management of Myelodysplastic Syndromes (New)

Multi-Site

- Systemic Therapy for Sarcoma (New)
- Treatment of Leptomeningeal Metastases (New)
- Treatment of Non-Melanoma Skin Cancer (New)

Resource Stratified

- Survivorship Care in Adolescents, Young Adults, and Adults (New)
- Geriatric Oncology (New)
- Treatment of Patients with Endometrial Cancer (New)

Supportive Care

- Integration of Patient-Reported Outcomes in Cancer Care (New)
- Management of Dermatologic Events from Cancer Treatment (New)
- Management of Treatment-Associated Interstitial Lung Disease (New)
- White Cell Growth Factors (Update)
- Central Venous Catheter Care (Update)

Patient & Survivor Care

- Management of Sleep Problems in Cancer Survivors (New)
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers (Update)
- Survivorship After Stem Cell Transplantation (New)

Thoracic Cancer

- Molecular Testing for the Selection of Patients with Lung Cancer for Treatment with Targeted Tyrosine Kinase Inhibitors Guideline Endorsement (Update of an endorsement)
- Management of Stage I Non-Small Cell Lung Cancer (New)
- The Role of CT Screening for Lung Cancer in Clinical Practice (Update)
- Duration of Systemic Therapy for Stage IV Lung Cancer (New)
- Management of Multifocal Lung Adenocarcinoma (New)

All Disease Sites													
Disease Site	Screening and Diagnosis			Treatment				Ongoing Care					
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Supportive Care		Survivorship		
Breast	1.05		1.02 1.03 1.04 1.06 1.15 1.30	1.02 1.20 1.21 1.24 1.27 1.29	1.01 1.21 1.24 1.27 1.29	1.07 1.17 1.21 1.23 1.27 1.31	1.08 1.09 1.14 1.17 1.18 1.21 1.25 1.30 1.31	1.10 1.22		8.07 8.19 9.08 12.04		9.13	
GI	2.09	2.09 2.16 12.05	2.04 2.06 2.08 2.14	2.08 2.09 2.12 2.13 2.14 12.06 12.07 2.24 P.01 P.02 P.03 P.04	2.08 2.11 2.12 2.13 2.14 2.17 2.18 2.19 2.20 12.06 12.07 2.24 P.01 P.03 P.04	2.01 2.08 2.11 2.12 2.13 2.14 2.17 2.18 2.19 2.20 12.06 12.07 2.24 P.01 P.03 P.04	2.20 2.21 2.22 2.23 2.24 P.01 P.03 P.04	2.02 2.08 2.09 12.06 12.07	3.21 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.101 8.102 8.11 8.12 8.14 8.16 8.17 8.18 8.20 8.22 8.23 8.24 8.25 8.26 8.27 9.08 12.04 P.07 P.23				
GU	3.19	3.04 P.12 3.24	3.03 3.15 3.16 3.18	3.08 3.11 3.14 3.17 P.05 P.08	3.08 3.09 3.11 3.13 3.14 3.17 3.18 3.22 P.05 P.08	3.02 3.05 3.11 3.14 3.22	3.01 3.06 3.08 3.11 3.14 3.18 3.20 3.22	3.10 3.12 3.18 P.14 P.15	8.07 8.08 8.101 8.102 8.11 8.12 8.14 8.16 8.17 8.18 8.20 8.22 8.23 8.24 8.25 8.26 8.27 9.08 12.04 P.07 P.23	3.21 13.01	9.01 9.02 9.03 9.07 9.08 9.16 P.26 P.27	9.05 9.09 9.12 9.13 9.15 P.06	
Gyn	12.01	12.02	11.03	12.03 12.08 P.11 P.12	11.01 12.03 12.08 P.07 P.09 P.11 P.12	11.02 12.03 12.08 P.09 P.11	11.04 12.03 12.08 P.11		13.01	9.05 9.12 9.15 P.10			
H&N			4.04 4.05	4.01 4.03 4.05 4.06 4.07 4.11	4.01 4.02 4.03 4.05 4.06 P.13	4.01 4.03 4.05 4.06 4.07	4.01 4.09		13.01	9.14			
Hem			5.02	P.17 P.18	P.17 P.18 P.19	5.03c P.17 P.18 P.19	5.01 P.17 P.18 P.19	5.03		9.05 9.15			
Neuro-onc	P.15	P.15	P.15	13.08	13.02 13.04 13.08	13.04 13.07			13.01 13.05	9.05 9.12 9.15			
Ophthalmic									13.01	9.05 9.12 9.15			
Pediatric-specific									8.09	9.17			
Sarcoma									13.01	9.05 9.12 9.15			
Skin			7.01	7.01		7.02	7.02	7.02	13.01 P.24	9.05 9.12 9.15			
Thoracic		6.04	6.02 6.05 6.08	6.01 6.07 6.08 P.28 P.30	6.01 6.06 6.08 6.09 6.11 6.12 P.28 P.29 P.30	6.01 6.031 6.032 6.07 6.08 6.11 P.28 P.29 P.30	6.031 6.032 6.13 P.28	6.10 P.28	13.01	9.05 9.12 9.15			

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Breast Cancer																		
Disease Site		Screening and Diagnosis			Treatment								Ongoing Care					
		Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery			Radiotherapy		Chemotherapy		Hormonal and Other Therapies		Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship	
DCIS		1.05			1.02	1.24		1.24										
Invasive Breast Cancer	BRCA1/BRCA2 Mutation					1.29		1.29			1.29							
	Hormone receptor-positive			1.02 1.03 1.06 1.30								1.14 1.18	1.08 1.09	1.22	1.10	8.07 9.08 12.04	8.19	9.13
	HER2-positive		1.04 1.15			1.21	1.20 1.27	1.21	1.01 1.27	1.23 1.27 1.31	1.07 1.21	1.21						
	HER2-negative										1.17	1.17						
	Triple-negative																	
Male Breast Cancer				1.30								1.30						

Blue Text: Current
 Gray Italics: Archived
 Green Text: Being Updated
 Red Text: New Guideline in Development
 Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
1.01	Breast	Postmastectomy Radiotherapy	Guideline Update	ASCO-ASTRO-SSO	Current	Abram Recht, Stephen Edge	9/3/2019
1.02	Breast	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer	Guideline Update	n/a	Current	Armando Giuliano, Gary Lyman	1/13/2020
1.03	Breast	HER2 Testing in Breast Cancer	Guideline Update	ASCO-CAP	In Progress	Antonio Wolff, Liz Hammond	6/25/2018
1.05	Breast	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction	Guideline Update	n/a	Current	Kala Visvanathan, Carol Fabian	9/6/2011
1.06	Breast	Estrogen and Progesterone Receptor Testing in Breast Cancer	Guideline Update	ASCO-CAP	Current	Kim Allison, Antonio Wolff	3/1/2012
1.07	Breast	Systemic Therapy for Patients With Advanced HER2–Positive Breast Cancer	Guideline Update	n/a	Current	Nancy Davidson, Sharon Giordano	7/29/2021
1.08	Breast	Role of Bone-Modifying Agents in Metastatic Breast Cancer	Guideline Update	ASCO-CCO	Current	Beverly Moy, Catherine Van Poznak	5/31/2019
1.09	Breast	Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Bi	Endorsement	CCO Endorsement	Archived		7/29/2021
1.10	Breast	Breast Cancer Follow-Up and Management After Primary Treatment	Guideline Update	n/a	Current	James Khatcheressian, Nancy Davidson	7/29/2021
1.14	Breast	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer Update	Guideline Update	n/a	In Progress	Harold Burstein, Jennifer Griggs	5/7/2014
1.15	Breast	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage I	Guideline Update	n/a	Current	Fabrice Andre, Vered Stearns	6/25/2018
1.17	Breast	Chemotherapy for HER2 Negative Advanced Breast Cancer	De Novo Guideline	n/a	Current	Beverly Moy, Lisa Carey	6/17/2019
1.18	Breast	Endocrine therapy for hormone receptor positive metastatic breast cancer	De Novo Guideline	n/a	Current	Harold Burstein	10/20/2020
1.20	Breast	Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Bre	Endorsement	SSO-ASTRO	Current	Thomas A. Buchholz, Lisa A. Newman	8/15/2016
1.21	Breast	Disease Management for Patients With Advanced HER2–Positive Breast Cancer and Brain Metastas	De Novo Guideline	n/a	Current	Naren Ramakrishna, Nancy Lin	3/6/2017
1.22	Breast	Endorsement of the Cancer Care Ontario patient/disease characteristics and recurrence risk recom	Endorsement	CCO Endorsement	Current	N. Lynn Henry, Vered Stearns	
1.23	Breast	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO	Guideline Update	CCO Adaptation	Current	Neelima Denduluri, Sharon Giordano	7/19/2021
1.24	Breast	Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ	De Novo Guideline	SSO-ASTRO-ASCO	Current	Monica Morrow	
1.25	Breast	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer	De Novo Guideline	CCO-ASCO	Current	Catherine Van Poznak, Andea Eisen	8/3/2021
1.26	Breast	Whole Breast Irradiation	Endorsement	ASTRO Endorsement	Current	Armando Giuliano, Abram Recht	2/14/2020
1.27	Breast	Management of the Axilla	De Novo Guideline	CCO-ASCO	Project Terminated	Muriel Brackstone	1/28/2021
1.28	Breast	Autologous Breast Reconstruction	Endorsement	ASPS Endorsement	Current	Colleen McCarthy, Kelly Hunt	
1.29	Breast	Hereditary Breast Cancer	De Novo Guideline	ASCO-ASTRO-SSO	Project Terminated	Nadine Tung, Dana Zakalik	4/3/2020
1.30	Breast	Management Male Breast Cancer	De Novo Guideline	n/a	Current	Sharon Giordano, Mike Hassett	2/14/2020
1.31	Breast	Neoadjuvant therapy in locally advanced breast cancer	De Novo Guideline	n/a	Current	Dawn Hershman, Larissa Korde	1/28/2021
8.19	Supportive Care	Integrative Therapies During and After Breast Cancer Treatment Endorsement	Endorsement	SIO Endorsement	Current	Gary Lyman, Lorenzo Cohen	6/11/2018
9.13	Survivorship	Breast Cancer Survivorship Care Guideline	De Novo Guideline	ACS-ASCO			12/7/2015

Gastrointestinal Cancer											
Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Biliary				2.24 P.01	2.24 P.01	2.18 2.24 P.01	2.22 2.23 2.24 P.01				
Colorectal	2.09	2.09 12.05	2.04 2.06	2.09 12.06 12.07 2.20 P.03 P.04	12.06 12.07 2.20 P.03 P.04	2.01 12.06 12.07 2.19 2.20 P.03 P.04	2.20 P.03 P.04	2.02 2.09 12.06 12.07			
Esophageal			2.08 2.14	2.08 2.14	2.08 2.14	2.08 2.14 2.21	2.21	2.08			
Liver						2.17					
Neuroendocrine											
Pancreatic		2.16		2.12	2.11 2.12 2.13	2.11 2.12 2.13					
Stomach		P.02	2.14 P.02	2.14 P.02	2.14	2.14					

Blue Text: Current
 Gray Italics: Archived
 Green Text: Being Updated
 Red Text: New Guideline in Development
 Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Year of Last Publication
2.01	Gastrointestinal	Adjuvant therapy for stage II colon cancer	Guideline Update		Current	Nancy Baxter, Jeffrey Meyerhardt	12/22/2021
2.02	Gastrointestinal	Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Colorectal Cancer	Endorsement	CCO Endorsement	Current	Al B. Benson, Jeffrey A. Meyerhardt	11/12/2013
2.04	Gastrointestinal	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-EGFR Therapy	Guideline Update	n/a	Archived	Carmen J. Allegra, Richard L. Schilsky	10/5/2015
2.06	Gastrointestinal	Molecular Markers for the Evaluation of Colorectal Cancer	De Novo Guideline	ASCP-CAP-AMP-ASCO	Current	Antonia Sepulveda (AMP), Wayne W. Grody (ASCP), Stephen J.ang (ASCO)	2/6/2017
2.08	Gastrointestinal	Treatment of Locally Advanced Esophageal Carcinoma	De Novo Guideline	n/a	Current	Manish Shah, Wayne Hofstetter	8/18/2021
2.09	Gastrointestinal	Hereditary Colorectal Cancer Syndromes: ASCO Endorsement of the Familial Risk Management Guidelines	Endorsement	ESMO Endorsement	Current	Paul Limburg, Elena Stoffel	12/1/2014
2.11	Gastrointestinal	Metastatic Pancreatic Cancer	Guideline Update	n/a	Current	Dan Laheru, Davendra Sohal	8/5/2020
2.12	Gastrointestinal	Resectable Pancreatic Cancer	Guideline Update	n/a	Current	Alok Khorana, Matt Katz	6/10/2019
2.13	Gastrointestinal	Locally Advanced Pancreatic Cancer	De Novo Guideline	n/a	Current	Ed Balaban, Nelson Yee	5/31/2016
2.14	Gastrointestinal	HER2 Testing in Gastric Cancer	De Novo Guideline	ASCO-CAP	Current	Angela Barley (CAP), Mary Kay Washington (ASCP), Jaffar A. Ajlani	11/14/2016
2.16	Gastrointestinal	Pancreatic Hereditary PCO	PCO	n/a	Current	Elena Stoffel, Alok Khorana	11/20/2018
2.17	Gastrointestinal	Systemic Therapy for Advanced Hepatocellular Carcinoma	De Novo Guideline	n/a	Current	John Gordan, Michal Rose	11/16/2020
2.18	Gastrointestinal	Adjuvant Therapy for Biliary Tract Cancer	De Novo Guideline	n/a	Current	Rachna Shroff, Shishir Maithel	3/11/2019
2.19	Gastrointestinal	Adjuvant therapy for stage III colon cancer	De Novo Guideline	n/a	Current	Nancy Baxter, Christopher Lieu	4/15/2019
2.20	Gastrointestinal	Treatment options for Advanced Colon Cancer	De Novo Guideline	n/a	In Progress	Cathy Eng, Van Morris	
2.21	Gastrointestinal	Targeted Therapy for Gastroesophageal Cancer	De Novo Guideline	n/a	In Progress	Manish Shah, Lakshmi Rajdev	
2.22	Gastrointestinal	Targeted Therapy and Immunotherapy for Advanced Cholangiocarcinoma	De Novo Guideline	n/a	In Progress		
2.23	Gastrointestinal	Systemic Therapy for Neuroendocrine Tumors	De Novo Guideline	n/a	In Progress		
2.24	Gastrointestinal	Neoadjuvant and Adjuvant Therapy for Rectal Cancer (including nonoperative approaches)	De Novo Guideline	n/a	In Progress		
12.05	Resource-Stratified	RSG CRC early detection	De Novo Guideline	n/a	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto L. Costas-Chavarri	2/25/2019
12.06	Resource-Stratified	RSG CRC tx early stage	De Novo Guideline	n/a	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto L. Costas-Chavarri	2/25/2019
12.07	Resource-Stratified	RSG CRC tx late stage	De Novo Guideline	n/a	Current	Gabriela Chiorean, Mary Chamberlin	
P.01	Gastrointestinal	Systemic Therapy (including Targeted Therapy) for Biliary Tract Cancer					
P.02	Gastrointestinal	Perioperative Management of Gastric Cancer with Diagnostic Laparoscopy and Nodal Dissection and Pathology					
P.03	Gastrointestinal	Treatment Options for Locoregional and Metastatic Small Bowel/Ampullary Cancer					
P.04	Gastrointestinal	Treatment Options for Anal Cancer					

Genitourinary Cancer											
Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Bladder				3.11 3.14	3.11 3.14	3.11 3.14	3.11 3.14		8.07 9.08 12.04	3.21 P.07	P.06
Kidney				3.08	3.08 3.22 P.08	3.22 P.08	3.08 3.22 P.08				P.06
Penile											P.06
Prostate	3.19	3.04 3.24	3.15 3.16 3.18	3.18 P.05	3.09 3.13 3.17 3.18 P.05	3.02 3.05	3.01 3.06 3.18 3.20	3.10 3.12 3.18			9.09 P.06
Germ Cell Tumors			3.03								P.06

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
3.01	Genitourinary	Initial Hormonal Management of Androgen-Sensitive Me	Guideline Update	n/a	Current	Kathy Virgo, James Talcott	1/26/2021
3.02	Genitourinary	Non-Hormonal Therapy for Men With Metastatic Hormo	Endorsement	CCO Endorsement	Archived		11/20/2007
3.03	Genitourinary	Uses of Serum Tumor Markers in Adult Males with Germ	De Novo Guideline	n/a	Current	Tim Gilligan, Dan Hayes	7/10/2010
3.04	Genitourinary	Screening for Prostate Cancer with Prostate-Specific Anti	PCO	n/a	Archived	Karen Hoffman, Robert Nam	2/16/2012
3.05	Genitourinary	Systemic Therapy for Metastatic Castration Resistant Pro	Guideline Update	n/a	Current	Ethan Basch	9/8/2014
						Katherine Virgo,	
3.06	Genitourinary	2nd Line Hormonal Therapy for Castration Resistant Pros	PCO	n/a	Current	Eric Singer	4/25/2017
3.08	Genitourinary	Management of small renal masses	De Novo Guideline	n/a	Current	Tony Finelli, Paul Russo	1/17/2017
3.09	Genitourinary	AUA/ASTRO CPG on adjuvant RT following radical prosta	Endorsement	AUA-ASTRO Endorser	Current	Howard Sandler, Stephen Freedland	11/3/2014
3.10	Genitourinary	Androgen deprivation therapy with or without chemothe	De Novo Guideline	n/a	Current	Matthew Milowsky, Cheryl Lee	3/21/2016
3.11	Genitourinary	Guidelines on muscle-invasive and metastatic bladder ca	Endorsement	EAU Endorsement	Current	Ronald Chen, Suniel Jain	2/16/2016
3.12	Genitourinary	Active Surveillance Endorsement	Endorsement	CCO Endorsement	Current	Andrew Loblaw, Joseph Chin	3/27/2017
3.13	Genitourinary	Brachytherapy in Prostate Cancer	Guideline Update	ASCO-CCO	Current		8/10/2017
3.14	Genitourinary	ASCO-AUA Bladder Cancer Guideline	De Novo Guideline	AUA-ASCO-ASTRO-SU	Current	Scott E. Eggener, AUA rep, Co-Chair, H	12/12/2019
3.15	Genitourinary	Guidelines for the use of molecular and cellular diagnosti	De Novo Guideline	ASCO-EAU-AUA-CAP	Current	Alberto Vargas, Edouard Trabulsi	1/15/2020
						Scott Morgan,	
3.16	Genitourinary	Optimum imaging strategies for advanced prostate cance	De Novo Guideline	ASCO-SAR-ACR-SNMM	Current	Howard Sandler	10/11/2018
3.17	Genitourinary	Hypofractionated RT for localized prostate cancer	De Novo Guideline	ASTRO-ASCO-AUA	Current	Karim Touijer, Andrew Stephenson, Jr	9/5/2018
3.18	Genitourinary	ASCO Endorsement of the AUA Localized prostate cancer	Endorsement	AUA Endorsement	Under Review for Update		3/20/2009
3.19	Genitourinary	Use of 5-alpha Reductase Inhibitors for Prostate Cancer	Guideline Update	ASCO-AUA	Current	Philip Saylor, Jeff Michalski	1/28/2020
3.20	Genitourinary	Bone Health and Bone-targeted Therapies for Prostate C	Endorsement	CCO Endorsement	In Progress		
3.21	Genitourinary	Special considerations for elderly patients with genitourinary cancers		n/a	In Progress	TBD	
3.22	Genitourinary	Management of metastatic renal clear cell cancer	De Novo Guideline	n/a	Current	Eric Singer, Kimryn Rathmell	
3.23	Genitourinary	Node Positive Prostate Cancer	De Novo Guideline	n/a	In Progress		
3.24	Genitourinary	Germline and Genomic Testing in Advanced Prostate Can	De Novo Guideline	n/a	In Progress		
P.05	Genitourinary	Primary Tumor-Directed and Metastasis-Directed Local Therapy in metastatic Prostate Cancer					
P.06	Genitourinary	Genitourinary Cancers Survivorship					
P.07	Genitourinary	Special Considerations for Elderly Patients with Genitourinary Cancers					
P.08	Genitourinary	Adjuvant Treatment of Localized and Oligometastatic RCC After Definitive Therapy					

Gynecologic Cancer

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Cervical	12.01	12.02		12.03 P.11	12.03 P.09 P.11	12.03 P.11	12.03 P.11				P.10
Endometrial/ Uterine				P.12	11.01 P.12						P.10
Ovarian			11.03	12.08	12.08	11.02 12.08 P.09	11.04 12.08				P.10
Vaginal											P.10
Vulvar											P.10

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
11.01	Gynecologic	Postoperative Radiation Therapy for Endometrial Cancer	Endorsement	ASTRO Endorsement	Current	Larissa Meyer, Alexi Wright	7/6/2015
11.02	Gynecologic	NACT for Newly Diagnosed, Advanced Ovarian Cancer	De Novo Guideline	ASCO-SGO	Current	Alexi Wright, Mitchell Edelson	8/8/2016
11.03	Gynecologic	Germline and somatic tumor testing	De Novo Guideline	n/a	Current	Christina Annunziata, Panos Konstantinopoulos	1/27/2020
11.04	Gynecologic	PARP Inhibitors in the Management of Ovarian Cancer	De Novo Guideline	n/a	Current	Bill Tew, Elise Kohn	8/13/2020
12.01	Resource-Stratified	Cervical Cancer Primary Prevention	De Novo Guideline	n/a	Current	Silvina Arrossi, Silvia de Sanjose	3/17/2017
12.02	Resource-Stratified	Cervical Cancer Secondary Prevention	De Novo Guideline	n/a	Current	Jose Jeronimo, Surenda Srinivas Shastri	10/12/2016
12.03	Resource-Stratified	Cervical Cancer Workup and Treatment	De Novo Guideline	n/a	Current	Jonathan Berek, Linus Chuang	5/25/2016
12.08	Resource-Stratified	RSG Ovarian Cancer	De Novo Guideline	n/a	Current	Jean Rene Clemenceau, Verna Vanderpuye	6/29/2021
P.09	Gynecologic	First Platinum-Sensitive ovarian cancer recurrence					
P.10	Gynecologic	Gynecologic Cancers Survivorship					
P.11	Gynecologic	Treatment of Invasive Cervical Cancer					
P.12	Gynecologic	Recurrent Endometrial Cancer					

Head and Neck Cancer

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Cross-cutting/ undefined scope				P.14 P.15 P.16	P.14 P.15 P.16	P.14 P.15 P.16	P.14 P.15 P.16		P.16		
Laryngeal and hypopharyngeal				4.01	4.01	4.01	4.01				9.14
Nasal cavity and paranasal sinus											
Nasopharyngeal							4.09				
Oral and oropharyngeal			4.04	4.03 4.06 4.11	4.02 4.03 4.06	4.03 4.06					
Salivary gland				4.07	4.07	4.07					
Thyroid					P.13						
Unknown Primary			4.04 4.05	4.05	4.05	4.05					

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
4.01	Head & Neck	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer	De Novo Guideline	n/a	Current	Arlene Forastiere, Greg Wolf	11/27/2017
4.02	Head & Neck	ASTRO Oropharyngeal Guideline Endorsement	Endorsement	ASTRO Endorsement	Current	Harry Quon, Arlene Forastiere, Neha	10/24/2017
4.03	Head & Neck	Management of the neck in newly diagnosed squamous cell head and neck cancer	De Novo Guideline	n/a	Current	Chris Holsinger, Shlomo Koyfman	2/27/2019
4.04	Head & Neck	HPV Testing in Head and Neck Squamous Cell Carcinoma	Endorsement	CAP Endorsement	Current	Bayardo Perez-Ordóñez, Carole Fakhri	9/6/2018
4.05	Head & Neck	Diagnosis and Management of Cancer of Unknown Primary in the Head and Neck	De Novo Guideline	n/a	Current	Ellie Maghami, Jimmy Caudell	4/23/2020
4.06	Head & Neck	Role of De-Escalation Protocols in the Management of p16+ Oropharyngeal Cancer	PCO	n/a	Current	David Adelstein, Drew Ridge	4/25/2019
4.07	Head & Neck	Management of salivary gland malignancy	De Novo Guideline	n/a	Current	Jessica Geiger, Patrick Ha	4/26/2021
4.08	Head & Neck	Treatment of Nasopharyngeal Cancer			Current	Jun Ma, Ying Sun	
4.09	Head & Neck	Use of immune checkpoint inhibitors and PD-L1 testing in HNSCC focusing on recurrent/metastatic disease			In Progress		
4.10	Head & Neck	ORN					
4.11	Head & Neck	Transoral Robotic Surgery for Oropharynx Cancer					
9.14	Survivorship	Head and Neck Cancer Survivorship Care Guideline	Endorsement	ACS Endorsement	Current	Larissa Nekhlyudov, Lillian Siu	2/27/2017
P.13	Head & Neck	Use of Systemic Treatment in the Management of Advanced Thyroid Cancer					
P.14	Head & Neck	Management of Advanced Cutaneous Squamous Cell of the Head and Neck					
P.15	Head & Neck	Management of Locoregionally Recurrent Head and Neck Cancer					
P.16	Head & Neck	Management of Head and Neck Cancers in the Very Elderly (80+) and/or Frail Patient Population					

Hematologic Malignancies

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Leukemia			5.02	P.17	P.17	P.17	P.17				
Non-Hodgkin lymphoma				P.18	P.18 P.19	P.18 P.19	P.18 P.19				
Hodgkin lymphoma											
Multiple myeloma						5.03	5.01	5.03			

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
5.01	Hematologic Mali	Bone Modifying Agents in Multiple Myeloma Update	Guideline Update	n/a	Current	Kenneth Anderson, Robert A. Kyle	1/17/2018
5.02	Hematologic Mali	CAP/ASH Acute Leukemia Endorsement	Endorsement	CAP-ASH Endorsement	Current	Valerie De Haas, Ling Zhang	12/3/2018
5.03	Hematologic Mali	Management of Patients with Multiple Myeloma	De Novo Guideline	n/a	Current	Joe Mikhael, Tom Martin	4/1/2019
P.17	Hematologic Mali	New Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia					
P.18	Hematologic Mali	New Treatment of Aggressive Lymphomas with a Focus on B Cell Lymphoma					
P.19	Hematologic Mali	New Risk-Based Management of Myelodysplastic Syndromes					

Neurooncology											
Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Femur				13.08	13.08						
Glioma					13.02	13.07					
Metastatic Brain Tumors					13.04 13.10	13.04	13.05			13.05	

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
13.02	Neurooncology	Radiation Therapy for Glioblastoma	Endorsement	ASTRO Endorsement	Current	Susan Chang, Eric Sulman	11/28/2016
13.04	Neurooncology	Treatment of Brain Metastases	De Novo Guideline	Society of Neuro-Oncology	Current	Michael Vogelbaum, David Schiff	12/21/2021
13.05	Neurooncology	Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors	Endorsement	Society of Neuro-Oncology	Current	Susan Chang, Michael Vogelbaum	3/18/2019
13.07	Neurooncology	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors	De Novo Guideline	n/a	Current	Nimish Mohile, Jaishri Blakeley	12/13/2021
13.08	Neurooncology	Treatment of Metastatic Carcinoma and Myeloma of the Femur	De Novo Guideline	MSTS-AAOS-ASCO	Current	David Schiff, Michael Vogelbaum	
13.10	Neurooncology	Radiation for Brain Metastases (ASTRO Endorsement)	Endorsement	ASTRO Endorsement	Current		

Resource-Stratified											
Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Breast				12.09	12.09	12.09	12.09		12.04		P.20
GI		12.05		12.06 12.07	12.06 12.07	12.06 12.07		12.06 12.07			
GU											
Geri Onc									12.04		P.20
Gyn	12.01	12.02		12.03 12.08 P.21 P.22	12.03 12.08 P.21 P.22	12.03 12.08 P.21 P.22	12.03 12.08 P.21 P.22		12.04 P.21		P.20
H&N											
Hem											
Neuro-onc											
Ophthalmic											
Pediatric											
Sarcoma											
Skin											
Thoracic											

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Status	Co-Chairs	Publication
12.01	Resource-Stratified	Cervical Cancer Primary Prevention	De Novo Guidelin	Current	Silvina Arrossi, Silvia de Sanjose	3/17/2017
12.02	Resource-Stratified	Cervical Cancer Secondary Prevention	De Novo Guidelin	Current	Jose Jeronimo, Surenda Srinivas Shastri	10/12/2016
12.03	Resource-Stratified	Cervical Cancer Workup and Treatment	De Novo Guidelin	Current	Jonathan Berek, Linus Chuang	5/25/2016
12.04	Resource-Stratified	Global Palliative Care	De Novo Guidelin	Current	Jim Cleary, Hibah Osman	5/8/2018
12.05	Resource-Stratified	RSG CRC early detection	De Novo Guidelin	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto Lopes, Manish Sh	2/25/2019
12.06	Resource-Stratified	RSG CRC tx early stage	De Novo Guidelin	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto Lopes, Manish Sh	2/25/2019
12.07	Resource-Stratified	RSG CRC tx late stage	De Novo Guidelin	Current	Gabriela Chiorean, Mary Chamberlin	3/9/2020
12.08	Resource-Stratified	RSG Ovarian Cancer	De Novo Guidelin	Current	Jean Rene Clemenceau, Verna Vanderpuye	6/29/2021
12.09	Resource-Stratified	RSG MBC adaptation	De Novo Guidelin	In Progress		
P.20	Resource-Stratified	Survivorship Care in Adolescents, Young Adults, and Adults				
P.21	Resource-Stratified	Geriatric Oncology				
P.22	Resource-Stratified	Treatment of Patients with Endometrial Cancer				

Supportive Care							
Disease-Specific		Mix of Cancer Types	Geriatric Oncology	Pediatric Oncology	Resource Stratified		
Breast	8.19	8.01 8.02	13.01	8.01 8.02 8.06 8.09 8.11	12.04	<div>Blue Text: Current</div> <div>Gray Italics: Archived</div> <div>Green Text: Being Updated</div> <div>Red Text: New Guideline in Development</div> <div>Purple Text: Priority for new guideline (also labeled "P")</div>	
GI		8.03 8.04					
GU		8.05 8.06					
Gyn		8.07 8.08					
H&N		8.09 8.101					
		8.102					
Hem		8.11 8.12					
		8.14					
Neuro-onc	13.05	8.16 8.17					
		8.18					
Opthalmic		8.20 8.22					
		8.23					
Sarcoma		8.24 8.25					
		8.26					
Skin	P.24	8.27 9.08					
Thoracic	P.25	12.04 P.23					
Project #	AG	Title					Type
8.01	Supportive Care	Platelet Transfusion for Patients With Cancer	Guideline Update	n/a	Current	Charles Schiffer, Ken Anderson	11/28/2017
8.02	Supportive Care	White Blood Cell Growth Factors	Guideline Update	n/a	Current	Thomas J. Smith, Jim Armitage	7/13/2015
8.03	Supportive Care	Use of Chemotherapy and Radiation Therapy Protectants Upda	Guideline Update	n/a	Archived	Martee L. Hensley, Lynn M Schuchter	1/1/2009
8.04	Supportive Care	Hepatitis B Virus Screening and Management for Patients with PCO		n/a	Current	Andrew S. Artz, Jessica P. Hwang	7/27/2020
8.05	Supportive Care	Management of Cancer-associated Anemia with ESAs	Guideline Update	ASCO-ASH	Current	Julia Bohlius, Alejandro Lazo-Langer	4/10/2019
8.06	Supportive Care	Antiemetics Update	Guideline Update	n/a	Current	Paul J. Hesketh, Mark G. Kris	7/13/2020
8.07	Supportive Care	The Integration of Palliative Care into Standard Oncology Care	Guideline Update	n/a	Under Review for	Thomas J. Smith, Betty R. Ferrell	10/31/2016
8.08	Supportive Care	Appropriate Chemotherapy Dosing for Obese Adult Patients W	Guideline Update	n/a	Current	Jennifer Griggs, Gary Lyman	5/3/2021
8.09	Supportive Care	Guideline for the Management of Fever and Neutropenia in Ch	Endorsement		Current		1/14/2013
8.101	Supportive Care	Outpatient Management of Fever and Neutropenia in Adult Pa	Guideline Update	ASCO-IDSA	Current	Christopher R. Flowers, Randy Taplitz	2/20/2018
8.102	Supportive Care	Antimicrobial Prophylaxis for Immunosuppression in Adults Tre	Guideline Update	ASCO-IDSA	Current	Christopher R. Flowers, Randy Taplitz	9/4/2018
8.11	Supportive Care	Central Venous Catheter Care	Guideline Update	n/a	Current		4/1/2013
8.12	Supportive Care	Venous Thromboembolism Prophylaxis and Treatment in Patie	Guideline Update	n/a	Current	Anna Falanga, Gary Lyman	8/5/2019
8.14	Supportive Care	Patient-Physician Communication	De Novo Guideline	n/a	Current	Walter Baile, Tim Gilligan	9/11/2017
8.16	Supportive Care	ISOO/ASCO Guideline on Osteonecrosis of the Jaw	De Novo Guideline	ISOO-ASCO	Current	Noam Yarom, Charles Shapiro	7/22/2019
8.17	Supportive Care	ISOO/ASCO Guideline on Salivary Gland Hypofunction/Xerostor	De Novo Guideline	ISOO-ASCO	Current	Siri Beier Jensen, Doug Peterson	7/20/2021
8.18	Supportive Care	ASCO/NCCN Immunotherapy Toxicities	De Novo Guideline	ASCO-NCCN	Current	Julie Brahmer (ASCO), John Thompson (NC	2/14/2018
8.19	Supportive Care	Integrative Therapies During and After Breast Cancer Treatmen	Endorsement	SIO Endorsement	Current	Gary Lyman, Lorenzo Cohen	6/11/2018
8.20	Supportive Care	Management of Cancer Cachexiaa	De Novo Guideline	n/a	Current	Eric Roeland, Charles Loprinzi	5/20/2020
8.22	Supportive Care	Opioid Use During Active Cancer Treatment	De Novo Guideline		Current		
8.23	Supportive Care	Diet, Physical Activity and Weight Management During Cancer	De Novo Guideline		Current		
8.24	Supportive Care	Management of Dyspnea	De Novo Guideline		Current	David Hui, Margaret Campbell	2/22/2021
8.25	Supportive Care	Cannabis					
8.26	Supportive Care	Opioid Conversion					
8.27	Supportive Care	Vaccination					
9.08	Survivorship	Chronic Pain	De Novo Guideline	n/a	Current	Judith Paice, Eduardo Bruera, Michael Levy	7/25/2016
10.01		Chemo Assays					
12.04	Resource-Stratified	Global Palliative Care	De Novo Guideline	n/a	Current	Jim Cleary, Hibah Osman	5/8/2018
13.01	Geriatric Oncology	Evaluation and Management of Vulnerabilities in Older Patient	De Novo Guideline	n/a	Under Review for	William Dale, Arti Hurria, Supriya Mohile	5/21/2018
13.05	Neurooncology	Anticonvulsant Prophylaxis and Steroid Use in Adults with Met:	Endorsement	CNS Endorsement	Current	Susan Chang, Michael Vogelbaum	3/18/2019
P.23	Supportive Care	Integration of Patient-Reported Outcomes in Cancer Care					
P.24	Supportive Care	Management of Dermatologic Events from Cancer Treatment					
P.25	Supportive Care	Management of Treatment-Associated Interstitial Lung Disease					

Blue Text: Current
Gray Italics: Archived
Green Text: Being Updated
Red Text: New Guideline in Development
Purple Text: Priority for new guideline (also labeled "P")

Survivorship							
Disease Site	Disease-Site Specific	Mix of cancer types					
Breast	9.13	9.01 9.02 9.03 9.07 9.08 9.16 9.17 9.18 P.26 P.27					
GI							
GU	9.09						
Gyn							
H&N	9.14						
Hem							
Neuro-onc							
Ophthalmic							
Pediatric	9.17						
Sarcoma							
Skin							
Thoracic							
Adult Cancers Only	9.05 9.12 9.15						
Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
9.01	Survivorship	Fertility Preservation in Patients with Cancer	Guideline Update	n/a	Current	Alison Loren, Kutluk Oktay	4/5/2018
9.02	Survivorship	Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Canc	Adaptation	CCO Adaptation	In Progress	Barbara L. Andersen, Julia H. Rowland	4/14/2014
9.03	Survivorship	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer	Adaptation	CCO Adaptation	In Progress	Julienne E. Bower, Karen Mustian	4/14/2014
9.05	Survivorship	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivo	De Novo Guideline	n/a	Current	Charles Loprinzi, Dawn Hershman	7/14/2020
9.07	Survivorship	Cardiac Dysfunction	De Novo Guideline	ASCO-ACC-AHA	Current	Saro Armenian, JB Durand	12/5/2016
9.08	Survivorship	Chronic Pain	De Novo Guideline	n/a	Current	Judith Paice, Eduardo Bruera, Michael Levy	7/25/2016
9.09	Survivorship	ACS's Prostate Cancer Survivorship Care Guideline	Endorsement	ACS Endorsement	Current	Matthew Resnick, David Penso	2/9/2015
9.12	Survivorship	Management of Osteoporosis in Survivors of Adult Cancers	De Novo Guideline	n/a	Current	Charles Shapiro, Joan Neuner	9/18/2019
9.13	Survivorship	Breast Cancer Survivorship Care Guideline	De Novo Guideline	ACS-ASCO	Current		12/7/2015
9.14	Survivorship	Head and Neck Cancer Survivorship Care Guideline	Endorsement	ACS Endorsement	Current	Larissa Nekhlyudov, Lillian Siu	2/27/2017
9.15	Survivorship	Interventions to Address Sexual Problems in People with Cancer	Adaptation	CCO Adaptation	Current	Julia Rowland, Jeanne Carter	12/11/2017
9.16	Survivorship	Integrative Approach to Cancer-Related Pain Management	De Novo Guideline	ASCO-SIO	Current		
9.17	Survivorship	Adolescent and Young Adult Survivorship	De Novo Guideline	n/a	In Progress		
9.18	Survivorship	Cancer During Pregnancy	De Novo Guideline	n/a	In Progress		
P.26	Survivorship	Management of Sleep Problems in Cancer Survivors					
P.27	Survivorship	Survivorship After Stem Cell Transplantation					

Thoracic Cancer

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Mesothelioma			6.08	6.08		6.08					
NSCLC		6.04	6.02 6.05	6.01 P.28	6.01 6.06 6.09 6.11 P.28	6.01 6.11 P.28	6.13 P.28	6.10			
SCLC		6.04	6.05	6.07	6.12 6.29	6.031 6.032 6.07 6.29	6.031 6.032 6.29	6.10			
Adenocarcinoma				P.30	P.30	P.30					

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
6.01	Thoracic	Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A	Guideline Update	ASCO-CCO	Current	Mark Kris, Laurie Gaspar	4/24/2017
6.02	Thoracic	Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients w	PCO	n/a	Archived		5/20/2011
6.031	Thoracic	Stage IV non-small-cell lung cancer (NSCLC)– non-driver alterations Guidel	Guideline Update	CCO	Current	Greg Masters, Nasser Hanna	1/28/2020
6.032	Thoracic	Stage IV non-small-cell lung cancer (NSCLC)– driver alterations Guideline	Guideline Update	CCO	Current	Greg Masters, Nasser Hanna	2/16/2021
6.04	Thoracic	The role of CT screening for Lung Cancer in clinical practice	De Novo Guidelin	n/a	Archived		5/20/2012
6.05	Thoracic	CAP/IASLC/AMP Molecular Testing Guideline for Selection of Lung Cancer	Endorsement	CAP-IASLC-AMP E	Current	Navneet Narula, Gregory Kalemkeria	2/5/2018
6.06	Thoracic	Radiotherapy in locally advanced non-small cell lung cancer	Endorsement	ASTRO Endorseme	Current	Christopher G. Azzoli, Andrea Bezjak	5/5/2015
6.07	Thoracic	Treatment of SCLC	Endorsement	ACCP Endorsemer	Current	Giseppe Giaccone, Charles Rudin	9/8/2015
6.08	Thoracic	Treatment of Malignant Pleural Mesothelioma	De Novo Guidelin	n/a	Current	Raffit Hassan, Hedy Kindler	1/18/2018
6.09	Thoracic	ASTRO Stereotactic Body Radiotherapy (SBRT) for Early Stage Non-small C	Endorsement	n/a	Current	Bryan Schneider, Brendon Stiles	11/6/2017
6.10	Thoracic	Lung Cancer Follow-Up	De Novo Guidelin	n/a	Current	Bryan Schneider, Nasser Altorki	12/12/2019
6.11	Thoracic	Management of Stage III NSCLC	De Novo Guidelin	n/a	Current		
6.12	Thoracic	Radiation Therapy for SCLC	Endorsement	ASTRO Endorseme	Current		1/27/2021
6.13	Thoracic	Systemic Therapy for SCLC	De Novo Guidelin	n/a	In Progress		
	Thoracic	Stage IV NSCLC Living Guideline			In Progress		
P.28	Thoracic	Management of Stage I Non-Small Cell Lung Cancer					
P.29	Thoracic	Duration of Systemic Therapy for Stage IV Lung Cancer					
P.30	Thoracic	Management of Multifocal Lung Adenocarcinoma					

Melanoma											
Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
All Disease Sites			7.01				7.02				

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development


Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
7.01	Melanoma	Sentinel Lymph Node Biopsy for Melanoma	Guideline Update	ASCO-SSO	Current	Sandra L. Wong, Gary H. Lyman	12/12/2017
7.02	Melanoma	Systemic Therapy for Stage II-IV Melanoma	De Novo Guideline	n/a	Current	Rahul Seth, Pauline Funchain	3/31/2020

Collaborating Organizations

- American Cancer Society
- American College of Cardiology
- American College of Chest Physicians
- American College of Radiology
- American Heart Association
- American Society for Clinical Pathology
- American Society for Radiation Oncology
- American Society of Echocardiography
- American Society of Hematology
- American Urological Association
- Association for Molecular Pathology
- Cancer Care Ontario
- Centers for Disease Control and Prevention
- College of American Pathologists
- Congress of Neurological Surgeons
- European Association of Urology
- European Society of Medical Oncology
- Hematology/Oncology Pharmacy Association
- Infectious Diseases Society of America
- International Association for the Study of Lung Cancer
- International Society of Oral Oncology
- Multinational Association of Supportive Care in Cancer
- Musculoskeletal Tumor Society
- National Cancer Institute Physician Data Query
- National Comprehensive Cancer Network
- Oncology Nursing Society
- Pediatric Oncology Group of Ontario
- Society for Immunotherapy of Cancer
- Society for Integrative Oncology
- Society for Neuro-Oncology
- Society of Abdominal Radiology
- Society of Gynecologic Oncology
- Society of Surgical Oncology
- Society of Urologic Oncology
- Society of Nuclear Medicine and Molecular Imaging
- U.S. Food and Drug Administration

Measures Overview



*14 measures are supported by ASCO Guidelines

Grants and Contracts

Society for Immunotherapy of Cancer (SITC) Measure Development Contract

Outcome: Two immunotherapy measures were developed, specified, and tested. Both measures were specified as Clinical Quality Measures (CQMs). In addition, ASCO populated the Call for Measures submission forms for CMS' Merit-based Incentive Payment System (MIPS) federal program. Once the measures are approved and added to the Measures Under Consideration (MUC), SITC staff will assume stewardship pre-rulemaking process with the goal of having them approved for use in the MIPS program.

1. Appropriate intervention of immune-related diarrhea and/or colitis in patients treated with immune checkpoint inhibitors
 - a. Was accepted to the 2021 MUC list and approved through rulemaking for inclusion in the 2023 CMS Merit-based Incentive Payment System (MIPS). SITC is now stewarding the measure.
 - b. ASCO and SITC are currently advocating for its addition to the new Advancing Cancer Care MIPS Value Pathway (MVP) through the new MVP maintenance process. This change would need to go through rulemaking. If approved, it would be added to the MVP for Performance Year 2024.
2. Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy
 - a. Was rejected from the 2022 MUC list. Per CMS "The measure does not meet the CMS fully developed definition with no empiric validity or patient encounter level/data

element testing. CMS will not be overturning any measure decisions provided in MERIT.” In summary, CMS changed some of the validity testing requirements between the time the Colitis measure was submitted (2021 MUC list) and when the PD-L1 measure was submitted (2022 MUC list).

- i. ASCO is now working in collaboration with SITC to complete the additional testing with volunteer practices. We have an aggressive timeline with the end goal being re-submission to the 2023 MUC list in May of 2023. Would then go through rule making for inclusion in MIPS for Performance Year 2024.

Gordon and Betty Moore Foundation Grant

Outcome: Two measures are in development. The measures emphasize the importance of biomarker testing in cancer care:

1. BRAF Mutational Analysis Results Received for Patients Treated for Metastatic Colorectal Cancer This electronic clinical quality measure (eCQM) has undergone full testing.
 - a. We recruited 5 practices and collected data on 146 patients.
 - b. Based on analysis, the measure is nearing topped out status (91% weighted average). Therefore, we do not plan to submit it to the MUC list for inclusion in MIPS. CMS is looking for measures with wide variations in practice and significant room for improvement, thus it would not be approved based on the current meaningful measures criteria.
 - c. This measure will be added to ASCO’s measure library for ASCO member practices to use for Quality Improvement.
 - d. We encountered limitations within the CancerLinQ platform, which prevent implementing at this time.
2. Appropriate Germline BRCA Testing for Ovarian Cancer Patients
The technical expert panel (TEP) had to walk the eCQM back to a CQM given the limitations to distinguishing between germline and somatic BRCA testing.
 - a. Specifications have been developed and we have recruited 13 practices to assist with the testing. We are working on data collection now.

Recent ASCO Technical Expert Panel (TEP) Activities

Immunotherapy TEP

1. Appropriate Management of Immune-Related Hepatic Toxicity for Patients Receiving Immune-Checkpoint Inhibitors (currently eCQM) (in development)

Stewarded Measures

Active ASCO Measures in PY2022 Federal Programs

Federal Program	Number of ASCO measures included
CMS Quality Payment Program (QPP) - Merit-based Incentive Payment System (MIPS)	11 (8 CQMs, 2 QCDR, 1 eCQM)
CMS PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program	4 (adapted for PCHQR hospital reporting)

Active ASCO Measures in PY2022 QPP MIPS

Measure Title	MIPS QCDR	MIPS CQM	MIPS eCQM	PCHQR	NQF Endorsed
Oncology: Medical and Radiation – Plan of Care for Pain	--	✓	--	--	✓
Oncology: Medical and Radiation – Pain Intensity Quantified (CQM)	--	✓	--	--	✓
Oncology: Medical and Radiation – Pain Intensity Quantified (eCQM)	--	--	✓	--	✓
Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer	--	✓	--	--	✓
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy	--	✓	--	--	✓
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies	--	✓	--	--	✓
Percentage of Patients who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)	--	✓	--	✓	✓
Percentage of Patients who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)	--	✓	--	✓	✓
Proportion of patients who died from cancer not admitted to hospice	--	--	--	✓	
Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days (lower score – better)	--	✓	--	✓	✓

Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents - Avoidance of Overuse (Lower Score - Better)	✓	--	--	--	--
Appropriate Antiemetic Therapy for High- and Moderate Emetic Risk Antineoplastic Agents	✓	--	--	--	--
Concurrent Chemo radiation for Patients with a Diagnosis of Stage IIIB NSCLC	✓	--	--	--	--

MIPS Performance Year 2022 Historical Benchmark Results

Measure Title	ID	Type	Avg Perf Rate	Decile 3	Decile 4	Decile 5	Decile 6	Decile 7	Decile 8	Decile 9	Decile 10	Topped Out	Seven Point Cap
Oncology: Medical and Radiation - Pain Intensity Quantified	143	MIPS CQM	89.61	90.82 - 96.59	96.60 - 98.73	98.74 - 99.74	99.75 - 99.99	--	--	--	100.00	Y	Y
Oncology: Medical and Radiation - Pain Intensity Quantified	143	eCQM	84.37	76.92 - 87.43	87.44 - 92.99	93.00 - 96.03	96.04 - 97.48	97.49 - 98.41	98.42 - 99.14	99.15 - 99.84	>= 99.85	Y	N
Oncology: Medical and Radiation - Plan of Care for Pain	144	MIPS CQM	80.53	64.63 - 79.58	79.59 - 87.49	87.50 - 93.54	93.55 - 97.12	97.13 - 99.15	99.16 - 99.99	--	100.00	N	N
Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer <i>Substantive changes to specification in PY 2021; PY 2022 measure can't be compared to PY 2020 measure</i>	450	MIPS CQM	--	--	--	--	--	--	--	--	--	--	--
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy <i>Insufficient volume of data submitted in PY 2020 to establish historical benchmark</i>	451	MIPS CQM	--	--	--	--	--	--	--	--	--	--	--
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies <i>Insufficient volume of data submitted in PY 2020 to establish historical benchmark</i>	452	MIPS CQM	--	--	--	--	--	--	--	--	--	--	--
Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better) <i>Insufficient volume of data submitted in PY 2020 to establish historical benchmark</i>	453	MIPS CQM	12.05	17.86 - 15.92	15.91 - 13.80	13.79 - 11.44	11.43 - 9.39	9.38 - 6.46	6.45 - 4.77	4.76 - 0.01	0.00	N	N
Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score - better)	455	MIPS CQM	--	--	--	--	--	--	--	--	--	--	--

Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better)	457	MIPS CQM	8.88	14.81 - 11.27	11.26 - 8.78	8.77 - 5.39	5.38 - 4.16	4.15 - 2.54	2.53 - 1.36	1.35 - 0.01	0.00	N	N
---	-----	-------------	------	------------------	-----------------	----------------	----------------	----------------	----------------	----------------	------	---	---

Core Quality Measures Collaborative (CQMC)


The CQMC defines a core measure set as a parsimonious group of scientifically sound measures that efficiently promote a patient-centered assessment of quality and should be prioritized for adoption in value-based purchasing and Alternative Payment Models (APMs). The CQMC has developed and released core sets of quality measures that could be implemented across both commercial and government payers. Ten of ASCO's measures are included in the 2022 Consensus Core Set for Medical Oncology.

ASCO Stewarded Measure Title	CQMC Consensus Core Set: Medical Oncology
Oncology: Medical and Radiation – Pain Intensity Quantified (CQM & eCQM)	✓
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy	✓
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies	✓
Percentage of Patients who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)	✓
Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life	✓
Percentage of Patients who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)	✓
Proportion of patients who died from cancer not admitted to hospice	✓
Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days (lower score – better)	✓
Trastuzumab administered to patients with AJCC stage I (T1c) – III and human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy	✓
RAS (KRAS or NRAS) gene mutation testing performed for patients with metastatic colorectal cancer who received anti-epidermal growth factor receptor monoclonal antibody therapy	✓

ASCO Stewarded Measures Utilized in ASCO Programs

Measure Title	Utilized in Quality Oncology Practice Initiative (QOPI®)	Utilized in CancerLinQ/ SmartLinQ
Oncology: Medical and Radiation – Pain Intensity Quantified (CQM)	✓	✓
Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer	--	✓
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies	✓	--
Percentage of Patients who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)	--	✓
Appropriate Antiemetic Therapy for High- and Moderate Emetic Antineoplastic Agents	✓	--

Volunteer Engagement



- **2 2022 FASCO Awardees**

Collaborating Organizations

- Alliance of Dedicated Cancer Centers (ADCC)
- American Academy of Hospice and Palliative Medicine (AAHPM)
- American Society for Radiation Oncology (ASTRO)
- Centers for Medicare and Medicaid Services (CMS)
- Cigna/Evernorth
- Core Quality Measures Collaborative (CQMC)
- Council for Medical Specialty Societies (CMSS)
- Gordon & Betty Moore Foundation
- Health Level Seven International (HL7) include CodeX (FHIR Accelerator Group) and minimal Common Oncology Data Elements (mCODE®)
- MITRE
- National Quality Forum (NQF)
- Patient-Reported Outcome Tools: Engaging Users and Stakeholder (PROTEUS) Collaborative funded by Genentech and PCORI
- Physician Clinical Registry Coalition
- Practice Insights by McKesson in Collaboration with The US Oncology Network (USON)
- Purchaser Business Group on Health (PBGH)
- Priority Health (MI private payor)
- Society for Immunotherapy of Cancer (SITC)
- Telligen
- United Healthcare (private payor)